US equities |
NVDA $239.24 ▲+0.14% MU $1,045.56 ▼-1.73% SPCX $171.92 ▲+0.49% AMD $649.42 ▲+2.80% MRVL $287.01 ▲+5.81% AVGO $375.81 ▲+3.67% INTC $112.50 ▼-3.18% MSFT $529.30 ▲+0.78%
FinancialContent

Cosmos Health Inc. - Common Stock (NQ:COSM)

0.3195 -0.0262 (-7.58%)
Delayed Quote Updated: 4:00 PM EDT, Oct 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cosmos Health Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
News headline image
Cosmos Health Advances International Patent Application for Its Proprietary Hydrogel Weight Management Platform Across the U.S., Europe, Australia, and Canada
From Cosmos Health Inc.
Via GlobeNewswire
News headline image
Cosmos Health’s C-Sept PRO Gains Strong Traction Across Leading Greek Public and Private Hospital Groups, With Annualized Sales Poised to Exceed $1.3 Million at Approximately 72% Gross Margin
From Cosmos Health Inc.
Via GlobeNewswire
News headline image
Cosmos Health Signs Agreement to Deploy Artificial Intelligence (AI)-Powered Call Center to Optimize Order Intake, Customer Communications, and Operating Efficiency
From Cosmos Health Inc.
Via GlobeNewswire
News headline image
Cosmos Health Builds Contract Manufacturing Orderbook to Over 25 Million Units; Division Positioned to Generate Over $10 Million in Recurring Annual Profit
From Cosmos Health Inc.
Via GlobeNewswire
News headline image
CosmoFarm Delivers Record Q2 2026 Revenue of Over $15M, Representing $60+ Million Annualized Run-Rate; Adds Over 80 Pharmacies and Expands AI Automation and Facility Capacity
From Cosmos Health Inc.
Via GlobeNewswire
News headline image
Cosmos Health Enters the $163 Billion Global Skincare Market; Sales Already Underway in the United States
From Cosmos Health Inc.
Via GlobeNewswire
Which stocks have an unusual volume on Wednesday? ↗
Via Chartmill
News headline image
Cosmos Health Signs 2.86 Million-Unit Contract Manufacturing Agreement With Pharmex S.A. Across Three Dermatological Products
From Cosmos Health Inc.
Via GlobeNewswire
Discover the most active stocks in Monday's session. ↗
Via Chartmill
News headline image
Cosmos Health Provides Update on United States Portfolio; Four 18 Series Products Introduced With Projected Annualized Revenue Over $22.7M and Approximately $17.0M Gross Profit
Company at a Turning Point — Moving the Business to a Different Level, With Growing Revenue and a Roadmap Toward Improved Profitability 
From Cosmos Health Inc.
Via GlobeNewswire
News headline image
Cosmos Health Receives New Contract Manufacturing Orders Totaling 253,657 Units Across a Range of Medicines
From Cosmos Health Inc.
Via GlobeNewswire
News headline image
Cosmos Health Reports Annualized Sales Exceeding $1.5M for Its C-Scrub and C-Sept Antiseptic Brands in the UK and Greece; Plans EU Expansion Targeting $7.4M in Revenue and $5.3M in Gross Profit
From Cosmos Health Inc.
Via GlobeNewswire
News headline image
Cosmos Health Signs LOI to Acquire Doc Pharma S.A., a European GMP Pharmaceutical Manufacturer, a Transformative Step Expected to Boost Assets, Profitability, Production Capacity, and Product Portfolio
From Cosmos Health Inc.
Via GlobeNewswire
News headline image
Cosmos Health Secures Additional 180-Day Nasdaq Extension to Regain Bid Price Compliance
From Cosmos Health Inc.
Via GlobeNewswire
News headline image
$20 Million in Liquid Assets Support Rapid Growth Including Acquisitions, Bio Pharma Production and Nanotechnology Initiatives for Diversified Global Heath Leader Cosmos Health, Inc. (Nasdaq: COSM)
Via Get News
Topics Artificial Intelligence Intellectual Property
News headline image
Cosmos Health Signs 3-Year Contract Manufacturing Agreement with Verisfield for 3.9 Million Units of VASCLOR GEST Progesterone Pessaries
From Cosmos Health Inc.
Via GlobeNewswire
News headline image
Cosmos Health CEO Issues Letter to Shareholders: Building an Innovative AI-Driven Global Healthcare Platform — Record Growth with U.S. Expansion Underway
From Cosmos Health Inc.
Via GlobeNewswire
News headline image
Cosmos Health Inaugurates State-of-the-Art Capsule Production Line with New 5-Year Contract Manufacturing Agreement with Provident Pharmaceuticals for 385,000 Units of CERTORUN
From Cosmos Health Inc.
Via GlobeNewswire
News headline image
Cosmos Health Completes Acquisition of Strategic Intellectual Property and Expands Nanotechnology Investment Initiatives
Strengthening proprietary IP portfolio and next-generation product development pipeline 
From Cosmos Health Inc.
Via GlobeNewswire
News headline image
Cosmos Health Continues U.S. Expansion with Launch of Oliv18, Targeting Cardiovascular and Antioxidant Categories
Science-backed, USDA and EU-certified, whole olive tree supplement for two major wellness categories — rapidly growing global market projected to exceed $33 billion 
From Cosmos Health Inc.
Via GlobeNewswire
News headline image
$65.3 Million Revenue in 2025 Followed by Q1 2026 Record of $17.9 Million with Momentum Continuing in Q2 for Diversified Global Heath Leader Cosmos Health Inc. (Nasdaq: COSM)
Via Get News
Topics Artificial Intelligence
News headline image
Cosmos Health Achieves Pan-European Distribution for Sky Premium Life Across All 27 EU Member States Through Leading E-Commerce Platform Skroutz
From Cosmos Health Inc.
Via GlobeNewswire
News headline image
Cosmos Health Identifies Approximately $20 Million in Non-Core Assets Available for Monetization to Accelerate Growth and Unlock Shareholder Value
From Cosmos Health Inc.
Via GlobeNewswire
News headline image
Cosmos Health Provides Balance Sheet Update: Highlights European Investment Bank Financing Discussions for up to €25M, Eliminates 38% of Warrant Overhang with No Dilution; Reaffirms Growth Trajectory; Notes No Known Business Reason for Recent Share Price
From Cosmos Health Inc.
Via GlobeNewswire
News headline image
Cosmos Health Enters $69 Billion Global Animal Health Industry with Veterinary C-Scrub Wash 4% Following Successful European Standard Testing Under EN 1656 and EN 1657
From Cosmos Health Inc.
Via GlobeNewswire
News headline image
Cosmos Health Releases 2026–2029 Guidance: Targeting $200M Revenue, $71M Gross Profit, and $44M Adjusted EBITDA by 2029 — Building an Innovative, High-Margin Healthcare Platform with Strong Cash Generation
From Cosmos Health Inc.
Via GlobeNewswire
News headline image
Cosmos Health Announces Expiration of 4,874,126 Series B Warrants Unexercised; ~38% of Total Outstanding Warrants
Via ACCESS Newswire
News headline image
Cosmos Health Reports Q1 2026 Results: Revenue Up 31% to $17.9M, New Q1 Record; Total Liabilities Reduced by $4.5M; Stockholders' Equity Up 7.6%; Cash of $2.2M; Record Momentum Continues into Q2 with U.S. Expansion Underway
Via ACCESS Newswire
News headline image
Cosmos Health, through its Subsidiary Cana Laboratories, Enters into an Advisory Agreement with the European Investment Bank (EIB) for the Financing of its €50M R&D Program; EIB Financing Represents up to 50%, or €25M, under the EIB's Venture Debt Program
Via ACCESS Newswire
News headline image
Cosmos Health Announces Withdrawal of Registration Statement on Form S-1
Via ACCESS Newswire
< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >